Skip to main content
Erschienen in: Tumor Biology 2/2014

01.02.2014 | Research Article

Gelatinase B (−1562C/T) polymorphism in tumor progression and invasion of breast cancer

verfasst von: P. Chiranjeevi, K. Mrudula Spurthi, N. Santhoshi Rani, G. Rajesh Kumar, T. Mohini Aiyengar, M. Saraswati, G. Srilatha, G. Kishore Kumar, Sudha Sinha, C. Sanjeeva Kumari, B. Nagarjuna Reddy, S. Vishnupriya, H. Surekha Rani

Erschienen in: Tumor Biology | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Matrix metalloproteinases (MMPs) play an important role in breast cancer tumor invasion and progression. MMP-9 is a member of the MMP family and is also known as Gelatinase B or type IV collagenases (92 kDa) and possesses proteolytic activity against type IV collagen, a major component of the basement membrane. Our study aims to examine the association of Gelatinase B (−1562C > T) promoter polymorphism with breast cancer invasion and progression. The study involves 200 breast cancer patients and age-matched 191 healthy controls. The SNP-1562C > T (rs3918242) in MMP-9 promoter region was examined by allele-specific polymerase chain reaction and gel electrophoresis. The genotypes were determined and compared between patients and controls, and the influence of the polymorphism on clinicopathological data was analyzed. The T allele of the -1562C > T MMP-9 polymorphism was detected more frequently in breast cancer patients than controls (p < 0.001). Our results suggest the clinical importance of MMP-9 gene polymorphism (−1562C > T) in breast cancer patients. The study may also help in identifying individuals at risk of developing breast cancer.
Literatur
1.
2.
Zurück zum Zitat Gaurav A, Pooja R, Ernesto R, Sa'nchez F, Jorge Carrasco R'n, Juan Manuel C, et al. Breast cancer care in developing countries. World J Surg. 2009;33:2069–76.CrossRef Gaurav A, Pooja R, Ernesto R, Sa'nchez F, Jorge Carrasco R'n, Juan Manuel C, et al. Breast cancer care in developing countries. World J Surg. 2009;33:2069–76.CrossRef
4.
Zurück zum Zitat Byrne C, Brinton LA, Haile RW, Schairer C. Heterogeneity of the effect of family history on breast cancer risk. Epidemiology. 1991;2:276–84.PubMedCrossRef Byrne C, Brinton LA, Haile RW, Schairer C. Heterogeneity of the effect of family history on breast cancer risk. Epidemiology. 1991;2:276–84.PubMedCrossRef
5.
Zurück zum Zitat Smith P, McGuffog L, Douglas F, Easton, et al. A genome wide linkage search for breast cancer susceptibility genes. Genes Chromosomes Cancer. 2006;45:646–55.PubMedCentralPubMedCrossRef Smith P, McGuffog L, Douglas F, Easton, et al. A genome wide linkage search for breast cancer susceptibility genes. Genes Chromosomes Cancer. 2006;45:646–55.PubMedCentralPubMedCrossRef
6.
Zurück zum Zitat Pakseresht S, Ingle GK, Bahadur AK, Ramteke VK, Singh MM, Garg S, et al. Risk factors with breast cancer among women in Delhi. Indian J Cancer. 2009;46:132–8.PubMedCrossRef Pakseresht S, Ingle GK, Bahadur AK, Ramteke VK, Singh MM, Garg S, et al. Risk factors with breast cancer among women in Delhi. Indian J Cancer. 2009;46:132–8.PubMedCrossRef
7.
Zurück zum Zitat Althuis DM, Dozier JM, Anderson FW, Devesa SS, Brinton LA. Global trends in breast cancer incidence and mortality. Int J Epidemiol. 1973–1997; 34:405–12. Althuis DM, Dozier JM, Anderson FW, Devesa SS, Brinton LA. Global trends in breast cancer incidence and mortality. Int J Epidemiol. 1973–1997; 34:405–12.
8.
Zurück zum Zitat Maller O, Martinson H, Schedin P. Extracellular matrix composition reveals complex and dynamic stromal-epithelial interactions in the mammary gland. J Mammary Gland Biol Neoplasia. 2010;15:301–18.PubMedCrossRef Maller O, Martinson H, Schedin P. Extracellular matrix composition reveals complex and dynamic stromal-epithelial interactions in the mammary gland. J Mammary Gland Biol Neoplasia. 2010;15:301–18.PubMedCrossRef
9.
10.
Zurück zum Zitat Forget MA, Desrosiers RR, Beliveau R. Physiological roles of matrix metalloproteinases: implications for tumor growth and metastasis. Can J Physiol Pharmacol. 1999;77:465–80.PubMedCrossRef Forget MA, Desrosiers RR, Beliveau R. Physiological roles of matrix metalloproteinases: implications for tumor growth and metastasis. Can J Physiol Pharmacol. 1999;77:465–80.PubMedCrossRef
11.
Zurück zum Zitat Kohn EC, Liotta LA. Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res. 1995;55:1856–62.PubMed Kohn EC, Liotta LA. Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res. 1995;55:1856–62.PubMed
13.
Zurück zum Zitat Jed F. Fisher, Shahriar Mobashery. Recent advances in MMP inhibitor design, Cancer Metastasis Rev.2006; 115–36. Jed F. Fisher, Shahriar Mobashery. Recent advances in MMP inhibitor design, Cancer Metastasis Rev.2006; 115–36.
14.
Zurück zum Zitat Ajay Kumar Chaudhary, Mamta Singh, Alok C Bharti, Kamlesh Asotra, Shanthy Sundaram and Ravi Mehrotra. Genetic polymorphisms of matrix metalloproteinases and their inhibitors in potentially malignant and malignant lesions of the head and neck, J Biol Chem. 2010; 17–10. Ajay Kumar Chaudhary, Mamta Singh, Alok C Bharti, Kamlesh Asotra, Shanthy Sundaram and Ravi Mehrotra. Genetic polymorphisms of matrix metalloproteinases and their inhibitors in potentially malignant and malignant lesions of the head and neck, J Biol Chem. 2010; 17–10.
15.
16.
Zurück zum Zitat Jones JL, Walker RA. Control of matrix metalloproteinase activity in cancer. J Pathol. 1997;183:377–9.PubMedCrossRef Jones JL, Walker RA. Control of matrix metalloproteinase activity in cancer. J Pathol. 1997;183:377–9.PubMedCrossRef
17.
Zurück zum Zitat McDonnell S, Navre M, Coffey Jr RJ, Matrisian LM. Expression and localization of matrix metalloproteinase pump-1 (MMP-7) in human gastric and colon carcinomas. Mol Carcinog. 1991;4:527–33.PubMedCrossRef McDonnell S, Navre M, Coffey Jr RJ, Matrisian LM. Expression and localization of matrix metalloproteinase pump-1 (MMP-7) in human gastric and colon carcinomas. Mol Carcinog. 1991;4:527–33.PubMedCrossRef
18.
Zurück zum Zitat Tu HF, Wu CH, Kao SY, Liu CJ, Liu TY, Lui MT. Functional −1562 C-to-T polymorphism in matrix metalloproteinase-9 (MMP-9) promoter is associated with the risk for oral squamous cell carcinoma in younger male areca users. J Oral Pathol Med. 2007;36:409–14.PubMedCrossRef Tu HF, Wu CH, Kao SY, Liu CJ, Liu TY, Lui MT. Functional −1562 C-to-T polymorphism in matrix metalloproteinase-9 (MMP-9) promoter is associated with the risk for oral squamous cell carcinoma in younger male areca users. J Oral Pathol Med. 2007;36:409–14.PubMedCrossRef
19.
Zurück zum Zitat Wu J, Zhang L, Luo H, Zhu Z, Zangh C, Hou Y. Association of matrix metalloproteinases-9 gene polymorphisms with genetic susceptibility to esophageal squamous cell carcinoma. DNA Cell Biol. 2008;27:553–7.PubMedCrossRef Wu J, Zhang L, Luo H, Zhu Z, Zangh C, Hou Y. Association of matrix metalloproteinases-9 gene polymorphisms with genetic susceptibility to esophageal squamous cell carcinoma. DNA Cell Biol. 2008;27:553–7.PubMedCrossRef
20.
21.
Zurück zum Zitat Kallakury BV et al. Increased expression of Matrix metalloproteinase 2 & 9 and tissue inhibitors of matrix metalloproteinase 1 & 2 correlates with poor prognostic variables in renal cell carcinoma. Clin Cancer Res. 2001;7:3113–9.PubMed Kallakury BV et al. Increased expression of Matrix metalloproteinase 2 & 9 and tissue inhibitors of matrix metalloproteinase 1 & 2 correlates with poor prognostic variables in renal cell carcinoma. Clin Cancer Res. 2001;7:3113–9.PubMed
22.
Zurück zum Zitat Baker EA, Leaper DJ. Measuring gelatinase activity in colorectal cancer. Eur J Surg Oncol. 2002;28:24–9.PubMedCrossRef Baker EA, Leaper DJ. Measuring gelatinase activity in colorectal cancer. Eur J Surg Oncol. 2002;28:24–9.PubMedCrossRef
23.
Zurück zum Zitat Tanioka Y, Yoshida T, Yagawa T, Saiki Y, Takeo S, Harada T, et al. Matrix metalloproteinase-7 and matrix metalloproteinase-9 are associated with unfavourable prognosis in superficial oesophageal cancer. Br J Cancer. 2003;89:2116–21.PubMedCentralPubMedCrossRef Tanioka Y, Yoshida T, Yagawa T, Saiki Y, Takeo S, Harada T, et al. Matrix metalloproteinase-7 and matrix metalloproteinase-9 are associated with unfavourable prognosis in superficial oesophageal cancer. Br J Cancer. 2003;89:2116–21.PubMedCentralPubMedCrossRef
24.
Zurück zum Zitat Ozalp S, Tanir HM, Yalcin OT, Kabukcuoglu S, Oner U, Uray M. Prognostic value of matrix metalloproteinase-9 (gelatinase-B) expression in epithelial ovarian tumors. Eur J Gynaecol Oncol. 2003;24:417–20.PubMed Ozalp S, Tanir HM, Yalcin OT, Kabukcuoglu S, Oner U, Uray M. Prognostic value of matrix metalloproteinase-9 (gelatinase-B) expression in epithelial ovarian tumors. Eur J Gynaecol Oncol. 2003;24:417–20.PubMed
25.
Zurück zum Zitat Sakata K, Satoh M, Someya M, Asanuma H, Nagakura H, Oouchi A, et al. Expression of matrix metalloproteinase 9 is a prognostic factor in patients with non-Hodgkin lymphoma. Cancer. 2004;100:356–65.PubMedCrossRef Sakata K, Satoh M, Someya M, Asanuma H, Nagakura H, Oouchi A, et al. Expression of matrix metalloproteinase 9 is a prognostic factor in patients with non-Hodgkin lymphoma. Cancer. 2004;100:356–65.PubMedCrossRef
26.
Zurück zum Zitat Lahiri DK, Nurnberger Jr JI. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res. 1991;19:5444.PubMedCentralPubMedCrossRef Lahiri DK, Nurnberger Jr JI. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res. 1991;19:5444.PubMedCentralPubMedCrossRef
27.
Zurück zum Zitat Raković MŽA, Stanković A. Allele-specific detection of C-1562T polymorphism in the matrix metalloproteinase-9 gene: genotyping by MADGE. Clin Biochem. 2006;39:630–2.PubMedCrossRef Raković MŽA, Stanković A. Allele-specific detection of C-1562T polymorphism in the matrix metalloproteinase-9 gene: genotyping by MADGE. Clin Biochem. 2006;39:630–2.PubMedCrossRef
28.
Zurück zum Zitat McCawley LJ, Matrisian LM. Matrix metalloproteinases: multifunctional contributors to tumor progression. Mol Med Today. 2000;6:149–56.PubMedCrossRef McCawley LJ, Matrisian LM. Matrix metalloproteinases: multifunctional contributors to tumor progression. Mol Med Today. 2000;6:149–56.PubMedCrossRef
29.
Zurück zum Zitat Venkateshwari AK, Sri M, Krishnaveni D, Pratibha N, Vidyasagar A, Jyothy A. Role of plasma MMP 9 levels in the pathogenesis of chronic pancreatitis. Ind J Clin Biochem. 2011;26:136–9.CrossRef Venkateshwari AK, Sri M, Krishnaveni D, Pratibha N, Vidyasagar A, Jyothy A. Role of plasma MMP 9 levels in the pathogenesis of chronic pancreatitis. Ind J Clin Biochem. 2011;26:136–9.CrossRef
30.
Zurück zum Zitat Turpeenniemi-Hujanen T. Gelatinases (MMP-2 and −9) and their natural inhibitors as prognostic indicators in solid cancers. Biochimie. 2005;87:287–97.PubMedCrossRef Turpeenniemi-Hujanen T. Gelatinases (MMP-2 and −9) and their natural inhibitors as prognostic indicators in solid cancers. Biochimie. 2005;87:287–97.PubMedCrossRef
31.
Zurück zum Zitat Onitilo AA, Engel JM, Greenlee RT, Mukesh BN. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathological features and survival. Clin Med Res. 2009;7:4–13.PubMedCentralPubMedCrossRef Onitilo AA, Engel JM, Greenlee RT, Mukesh BN. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathological features and survival. Clin Med Res. 2009;7:4–13.PubMedCentralPubMedCrossRef
32.
Zurück zum Zitat Henderson IC, Patek AJ. The relationship between prognostic and predictive factors in the management of breast cancer. Breast Cancer Res Treat. 1998;52:261–88.PubMedCrossRef Henderson IC, Patek AJ. The relationship between prognostic and predictive factors in the management of breast cancer. Breast Cancer Res Treat. 1998;52:261–88.PubMedCrossRef
33.
Zurück zum Zitat Rose DP, Royak-Schaler R. Tumor biology and prognosis in black breast cancer patients: a review. Cancer Detect Prev. 2001;25:16–31.PubMed Rose DP, Royak-Schaler R. Tumor biology and prognosis in black breast cancer patients: a review. Cancer Detect Prev. 2001;25:16–31.PubMed
34.
Zurück zum Zitat Zhang S, Li L, Lin JY, Lin H. Imbalance between expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in invasiveness and metastasis of human gastric carcinoma. World J Gastroenterol. 2003;9:899–04.PubMed Zhang S, Li L, Lin JY, Lin H. Imbalance between expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in invasiveness and metastasis of human gastric carcinoma. World J Gastroenterol. 2003;9:899–04.PubMed
35.
Zurück zum Zitat Zhang B, Ye S, Herrmann SM, Eriksson P, de Maat M, Evans A, et al. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation. 1999;99:1788–94.PubMedCrossRef Zhang B, Ye S, Herrmann SM, Eriksson P, de Maat M, Evans A, et al. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation. 1999;99:1788–94.PubMedCrossRef
36.
Zurück zum Zitat Baker EA, Leaper DJ. The plasminogen activator and matrix metalloproteinase systems in colorectal cancer: relationship to tumour pathology. Eur J Cancer. 2003;39:981–8.PubMedCrossRef Baker EA, Leaper DJ. The plasminogen activator and matrix metalloproteinase systems in colorectal cancer: relationship to tumour pathology. Eur J Cancer. 2003;39:981–8.PubMedCrossRef
37.
Zurück zum Zitat Zhou Y, Chunyuan Y, Miao X, Tan W, Liang G, Xiong P, et al. Substantial reduction in risk of breast cancer associated with genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes. Carcinogenesis. 2004;25:399–04.PubMedCrossRef Zhou Y, Chunyuan Y, Miao X, Tan W, Liang G, Xiong P, et al. Substantial reduction in risk of breast cancer associated with genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes. Carcinogenesis. 2004;25:399–04.PubMedCrossRef
38.
Zurück zum Zitat Stamenkovic I. Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol. 2000;10:415–33.PubMedCrossRef Stamenkovic I. Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol. 2000;10:415–33.PubMedCrossRef
39.
Zurück zum Zitat Srivastava P, Mandhani A, Kapoor R, Mittal RD. Role of MMP-3 and MMP-9 and their haplotypes in risk of bladder cancer in North Indian cohort. Ann Surg Oncol. 2010;17:3068–75.PubMedCrossRef Srivastava P, Mandhani A, Kapoor R, Mittal RD. Role of MMP-3 and MMP-9 and their haplotypes in risk of bladder cancer in North Indian cohort. Ann Surg Oncol. 2010;17:3068–75.PubMedCrossRef
40.
Zurück zum Zitat Przybylowska K, Kluczna A, Zadrozny M, Krawczyk T, Kulig A, Rykala J, et al. Polymorphisms of the promoter regions of matrix metalloproteinases genes MMP-1 and MMP-9 in breast cancer. Breast Cancer Res Treat. 2006;95:65–72.PubMedCrossRef Przybylowska K, Kluczna A, Zadrozny M, Krawczyk T, Kulig A, Rykala J, et al. Polymorphisms of the promoter regions of matrix metalloproteinases genes MMP-1 and MMP-9 in breast cancer. Breast Cancer Res Treat. 2006;95:65–72.PubMedCrossRef
41.
Zurück zum Zitat Zheng H, Takahashi H, Murai Y, Cui Z, Nomoto K, Niwa H, et al. Expressions of MMP-2, MMP-9 and VEGF are closely linked to growth, invasion, metastasis and angiogenesis of gastric carcinoma. Anticancer Res. 2006;26:3579–83.PubMed Zheng H, Takahashi H, Murai Y, Cui Z, Nomoto K, Niwa H, et al. Expressions of MMP-2, MMP-9 and VEGF are closely linked to growth, invasion, metastasis and angiogenesis of gastric carcinoma. Anticancer Res. 2006;26:3579–83.PubMed
42.
Zurück zum Zitat Ishimaru H, Kageyama Y, Hayashi T, Nemoto T, Eishi Y, Kihara K. Expression of matrix metalloproteinase-9 and bombesin/gastrin-releasing peptide in human prostate cancers and their lymph node metastases. Acta Oncol. 2002;41:289–96.PubMedCrossRef Ishimaru H, Kageyama Y, Hayashi T, Nemoto T, Eishi Y, Kihara K. Expression of matrix metalloproteinase-9 and bombesin/gastrin-releasing peptide in human prostate cancers and their lymph node metastases. Acta Oncol. 2002;41:289–96.PubMedCrossRef
43.
Zurück zum Zitat Gum R, Lengyel E, Juarez J, Chen JH, Sato H, Seiki M, et al. Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogen activated protein kinase kinase 1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP-1 sequences. J Biol Chem. 1996;271:10672–80.PubMedCrossRef Gum R, Lengyel E, Juarez J, Chen JH, Sato H, Seiki M, et al. Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogen activated protein kinase kinase 1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP-1 sequences. J Biol Chem. 1996;271:10672–80.PubMedCrossRef
44.
Zurück zum Zitat Shibao TK, Tsurudome Y, Hirata K, Nagata N, Itoh H. Lymphatic microvessel density is an independent prognostic factor in colorectal cancer. Dis Colon Rectum. 2007;50:308–14.PubMedCrossRef Shibao TK, Tsurudome Y, Hirata K, Nagata N, Itoh H. Lymphatic microvessel density is an independent prognostic factor in colorectal cancer. Dis Colon Rectum. 2007;50:308–14.PubMedCrossRef
45.
Zurück zum Zitat Shu Y. Influence of matrix metalloproteinase genotype on cardiovascular disease susceptibility and outcome. Cardiovasc Res. 2006;69:636–45.CrossRef Shu Y. Influence of matrix metalloproteinase genotype on cardiovascular disease susceptibility and outcome. Cardiovasc Res. 2006;69:636–45.CrossRef
Metadaten
Titel
Gelatinase B (−1562C/T) polymorphism in tumor progression and invasion of breast cancer
verfasst von
P. Chiranjeevi
K. Mrudula Spurthi
N. Santhoshi Rani
G. Rajesh Kumar
T. Mohini Aiyengar
M. Saraswati
G. Srilatha
G. Kishore Kumar
Sudha Sinha
C. Sanjeeva Kumari
B. Nagarjuna Reddy
S. Vishnupriya
H. Surekha Rani
Publikationsdatum
01.02.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 2/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1181-5

Weitere Artikel der Ausgabe 2/2014

Tumor Biology 2/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.